Individual differences and evidence-based psychopharmacology

BMC Medicine

Volumn 10, Issue , 2012, Pages

  Belmaker, R H ^a   Bersudsky, Yuly ^a   Agam, Galila ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Clinical Trials; Individual Differences; Measurement Error; Replicability; Variability; Variance

Indexed keywords

ADRENALIN; IMIPRAMINE; LITHIUM; PLACEBO; QUETIAPINE; VALNOCTAMIDE;

BIPOLAR DEPRESSION; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL HISTORY; NONHUMAN; NOTE; PERSONALIZED MEDICINE; PSYCHOPHARMACOLOGY;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; INDIVIDUALITY; MENTAL DISORDERS; MICE; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS; TREATMENT OUTCOME;

EID: 84866661115     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-10-110     Document Type: Note

References (11)

1. Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA 2007, 298(10):1209-1212. 10.1001/jama.298.10.1209, 17848656.
2. Ebstein R, Belmaker R, Grunhaus L, Rimon R. Lithium inhibition of adrenaline-stimulated adenylate cyclase in humans. Nature 1976, 259(5542):411-413. 10.1038/259411a0, 175287.
3. Bersudsky Y, Shaldubina A, Agam G, Berry GT, Belmaker RH. Homozygote inositol transporter knockout mice show a lithium-like phenotype. Bipolar Disord 2008, 10(4):453-459. 10.1111/j.1399-5618.2007.00546.x, 18452441.
4. Pickrell JK, Pai AA, Gilad Y, Pritchard JK. Noisy splicing drives mRNA isoform diversity in human cells. PLoS Genet 2010, 6(12):e1001236. 10.1371/journal.pgen.1001236, 3000347, 21151575.
5. Taniguchi Y, Choi PJ, Li GW, Chen H, Babu M, Hearn J, Emili A, Xie XS. Quantifying E. coli proteome and transcriptome with single-molecule sensitivity in single cells. Science 2010, 329(5991):533-538. 10.1126/science.1188308, 2922915, 20671182.
6. Bersudsky Y, Applebaum J, Gaiduk Y, Sharony L, Mishory A, Podberezsky A, Agam G, Belmaker RH. Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial. Bipolar Disord 2010, 12(4):376-382. 10.1111/j.1399-5618.2010.00828.x, 20636634.
7. Vieta E, Calabrese JR, Goikolea JM, Raines S, Macfadden W. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2007, 9(4):413-425. 10.1111/j.1399-5618.2007.00479.x, 17547587.
8. Lichtenberg P, Belmaker RH. Subtyping major depressive disorder. Psychother Psychosom 2010, 79(3):131-135. 10.1159/000286957, 20185969.
9. Belmaker RH. Patient history must be incorporated into any guidelines. Bipolar Disord 2009, 11(7):772. author reply 773, 10.1111/j.1399-5618.2009.00743.x, 19840001.
10. Kent DM, Shah ND. Risk models and patient-centered evidence: should physicians expect one right answer?. JAMA 2012, 307(15):1585-1586. 10.1001/jama.2012.469, 22511683.
11. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials 2010, 11:85. 10.1186/1745-6215-11-85, 2928211, 20704705.